



Contact:
Bill Enright
President & CEO
Phone: 205-909-3751
Email: enright@vaxin.com

FOR IMMEDIATE RELEASE

VAXIN ANNOUNCES APPOINTMENT OF DR. DAVID DRUTZ CHAIRMAN

Rockville, MD – October 13, 2011 – Vaxin Inc., a clinical stage vaccine development company today announced that Dr. David J. Drutz has been elected Chairman of the Board. Dr. Drutz has an esteemed career in medicine, significant management and clinical development experience in both pharmaceutical and biotechnology companies as well as successful venture capital experience. Dr. Drutz joined Vaxin's Board in January 2010 and currently also serves as Chair of the Compensation Committee.

"We are delighted to have someone with David's background and experience step up and take the helm at such an exciting time in Vaxin's growth," said Bill Enright, Chief Executive Officer of Vaxin. "His background in infectious disease, knowledge of the industry and leadership skills are tremendous assets that will be invaluable as we continue to advance our NasoVAX influenza and AdVAV anthrax vaccine candidates and position them for commercial success."

Dr. Drutz was recently elected Chairman of the Board of Gentris Corporation, Morrisville, NC (private), serves as a Director on two publicly traded companies DARA Biosciences (DARA:NASDAQ), Raleigh, NC, and MethylGene Inc., Montreal, Quebec, Canada (MYG:TSX) and recently resigned after 11 years as the Chairman of Tranzyme (TZYM:NASDAQ) after the filing of its IPO.

David J. Drutz, M.D., is President of Pacific Biopharma Associates, LLC, a biotechnology consulting firm based in Chapel Hill, North Carolina and a co-founder and former General Partner of Pacific Rim Ventures Company Ltd., an international life science investment company based in Tokyo, Japan. Dr. Drutz's management experience includes tenures as VP Biological Sciences at Smith Kline & French Laboratories, VP Clinical Development at Daiichi Pharmaceutical Corporation, and CEO of several biotechnology companies. Earlier in his career, Dr. Drutz was Professor of Medicine and Chief of the Division of Infectious Diseases at the University of Texas Health Science Center, San Antonio and prior to that appointment was Assistant Professor of Medicine and Chief of the Division of Infectious Diseases at the University of California, San Francisco/San Francisco General Hospital. Dr. Drutz received his M.D. from the University of Louisville School of Medicine in Louisville, Kentucky and postgraduate training in internal medicine and infectious diseases at Vanderbilt University School of Medicine, serving subsequently as a research medical officer (infectious diseases) in the U.S. Navy. He is a fellow of the American College of Physicians and the Infectious Diseases

Society of America and the author of more than 200 peer-reviewed articles, book chapters and abstracts for presentation.

About Vaxin:

Vaxin Inc. is a clinical stage biotechnology company, founded in December 1997 with facilities in Rockville, MD and Birmingham, AL, developing next generation vaccines to address significant public health and biodefense needs. Vaxin is focused on vaccines designed to protect people against influenza and anthrax infection using proprietary, patented technologies for intranasal delivery, and is also developing unique *in ovo* vaccines for preventing influenza outbreaks in poultry populations. Vaxin's vaccines are designed to provide a safe, effective, easily administered, rapidly manufactured, and cost-competitive alternative to currently marketed products. Vaxin's intranasally delivered, adenovirus-based vaccines have successfully completed pre-clinical development, Investigational New Drug (IND) review and Phase 1 clinical studies of NasoVAX for seasonal and pre-pandemic influenza indications, demonstrating both proof-of-concept in man and providing an initial safety assessment of the technology platform. The intranasal seasonal influenza vaccine induced a positive immune response (seroconversion) in 83% of patients, while the pre-pandemic influenza vaccine also shows promising signs of immunogenicity in a dose dependent manner. Phase 1 study reports indicate that both were safe and well tolerated. The proposed vectored anthrax vaccine product, AdVAV, is identical in route of administration, structure and manufacturing to these influenza candidates with the exception of the encoded antigen (*Bacillus anthracis* PA rather than *influenza virus* HA). It is expected that a nasal anthrax vaccine would greatly boost vaccine coverage against a bioterrorist attack during a crisis, and significantly reduce adverse side effects when compared to those induced by systemically-delivered anthrax vaccines. Vaxin recently received a significant BARDA contract to advance this vaccine through Phase 1 clinical studies should the contract option be exercised.

Forward-looking statements:

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

#